Home » Stocks » Arvinas

Arvinas, Inc. (ARVN)

Stock Price: $21.05 USD 0.48 (2.33%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 825.95M
Revenue (ttm) 46.93M
Net Income (ttm) -85.69M
Shares Out 39.24M
EPS (ttm) -2.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $21.05
Previous Close $20.57
Change ($) 0.48
Change (%) 2.33%
Day's Open 20.65
Day's Range 20.54 - 21.68
Day's Volume 298,974
52-Week Range 19.33 - 61.57

More Stats

Market Cap 825.95M
Enterprise Value 587.76M
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 39.24M
Float 26.65M
EPS (basic) -2.34
EPS (diluted) -2.35
FCF / Share -1.52
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.67M
Short Ratio 11.83
Short % of Float 21.28%
Beta 1.49
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 17.60
PB Ratio 4.18
Revenue 46.93M
Operating Income -67.18M
Net Income -85.69M
Free Cash Flow -58.84M
Net Cash 238.19M
Net Cash / Share 6.07
Gross Margin 91.57%
Operating Margin -143.15%
Profit Margin -182.60%
FCF Margin -125.38%
ROA -19.32%
ROE -54.53%
ROIC -39.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 10
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$60.80*
(188.84% upside)
Low
36.0
Current: $21.05
High
79.0
Target: 60.80
*Average 12-month price target from 10 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue42.9814.327.586.67
Revenue Growth200.03%89%13.64%-
Gross Profit42.9814.327.586.67
Operating Income-51.52-43.80-24.76-16.47
Net Income-70.29-41.48-24.05-14.35
Shares Outstanding32.939.421.906.17
Earnings Per Share-2.13-25.45-15.08-2.00
Operating Cash Flow-40.63-16.125.11-19.40
Capital Expenditures-6.24-2.83-1.01-0.26
Free Cash Flow-46.87-18.954.10-19.66
Cash & Equivalents28118839.1935.58
Total Debt4.392.150.310.45
Net Cash / Debt27618638.8835.12
Assets30219966.8537.94
Liabilities74.9662.6166.6013.91
Book Value227137-61.23-32.88
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Arvinas, Inc.
Country United States
Employees 133
CEO John G. Houston

Stock Information

Ticker Symbol ARVN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ARVN
IPO Date September 27, 2018

Description

Arvinas, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.